ST12
MCID: SPP011
MIFTS: 59

Suppression of Tumorigenicity 12 (ST12)

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Suppression of Tumorigenicity 12

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 56
Prostate Adenocarcinoma 56 12 13 15 17
Adenocarcinoma of Prostate 6 71
Prostate Adenocarcinoma 1; Pac1 56
Prostate Adenocarcinoma 1 56
St12 56
Pac1 56

Classifications:



External Ids:

Disease Ontology 12 DOID:2526
OMIM 56 601188
NCIt 49 C2919
SNOMED-CT 67 399490008
UMLS 71 C0007112

Summaries for Suppression of Tumorigenicity 12

Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to prostatic acinar adenocarcinoma and adenocarcinoma. An important gene associated with Suppression of Tumorigenicity 12 is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Deubiquitination. The drugs Fesoterodine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are Decreased sensitivity to paclitaxel and cardiovascular system

More information from OMIM: 601188

Related Diseases for Suppression of Tumorigenicity 12

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 638)
# Related Disease Score Top Affiliating Genes
1 prostatic acinar adenocarcinoma 34.0 TMPRSS2 NKX3-1 KLK3 AR
2 adenocarcinoma 33.7 U2AF1 TP53 SMAD4 PTEN PIK3CA KLK3
3 prostate cancer 33.4 TP53 TMPRSS2 SMAD4 SERPINA3 PTEN PIK3CA
4 prostatic hyperplasia, benign 32.5 SERPINA3 KLK3 AR
5 prostatic hypertrophy 32.5 SERPINA3 KLK3 AR
6 transitional cell carcinoma 32.3 U2AF1 TP53 PTEN PIK3CA KLK3 HRAS
7 prostatitis 32.2 TP53 SERPINA3 NKX3-1 KLK3 AR
8 bladder cancer 32.2 TP53 PTEN PIK3CA MIR199A1 MIR145 HRAS
9 breast cancer 32.1 TP53 SMAD4 SERPINA3 PTEN PIK3CA MIR199A1
10 meningioma, familial 32.1 TP53 SERPINA3 PTEN PIK3CA IDH1 H2AC18
11 lung cancer 32.1 U2AF1 TP53 SMAD4 SERPINA3 PTEN PIK3CA
12 colorectal cancer 32.1 U2AF1 TP53 SMAD4 SERPINA3 PTEN PIK3CA
13 prostate disease 32.0 SERPINA3 MIR331 MIR199A1 MIR145 KLK3 H2AC18
14 myeloma, multiple 32.0 U2AF1 TP53 SERPINA3 PTEN MIR331 MIR199A1
15 small cell carcinoma 31.9 TP53 TMPRSS2 PTEN KLK3 AR
16 in situ carcinoma 31.9 TP53 SERPINA3 PTEN PIK3CA HRAS H2AC18
17 adenoma 31.9 TP53 SMAD4 PIK3CA CTNNB1 BRAF
18 bladder urothelial carcinoma 31.9 U2AF1 TP53 PTEN PIK3CA KLK3 IDH1
19 leukemia, chronic lymphocytic 31.7 U2AF1 TP53 PTEN PIK3CA MIR199A1 MIR145
20 pancreatic cancer 31.7 TP53 SMAD4 SERPINA3 PTEN PIK3CA MIR199A1
21 renal cell carcinoma, nonpapillary 31.7 TP53 PTEN PIK3CA MIR199A1 MIR145 HRAS
22 squamous cell carcinoma, head and neck 31.7 U2AF1 TP53 SMAD4 PTEN PIK3CA MIR331
23 endometrial cancer 31.7 TP53 SMAD4 SERPINA3 PTEN PIK3CA MIR199A1
24 carcinosarcoma 31.7 TP53 PTEN PIK3CA HRAS CTNNB1
25 rectum adenocarcinoma 31.6 TP53 PIK3CA HRAS CTNNB1
26 sarcoma 31.6 TP53 SERPINA3 PIK3CA HRAS CTNNB1 BRAF
27 melanoma 31.6 TP53 PTEN PIK3CA MIR331 IDH1 HRAS
28 squamous cell carcinoma 31.6 U2AF1 TP53 SMAD4 PTEN PIK3CA HRAS
29 thyroid tumor 31.6 TP53 PTEN PIK3CA HRAS BRAF
30 hepatocellular carcinoma 31.5 TP53 SMAD4 SERPINA3 PTEN PIK3CA MIR199A1
31 leukemia, acute myeloid 31.5 U2AF1 TP53 SERPINA3 PTEN PIK3CA MIR331
32 adenosquamous carcinoma 31.5 TP53 SMAD4 SERPINA3 PTEN PIK3CA AR
33 melanoma, uveal 31.4 U2AF1 TP53 SMAD4 PTEN PIK3CA MIR199A1
34 clear cell adenocarcinoma 31.4 TP53 SMAD4 PIK3CA KLK3
35 penile cancer 31.4 TP53 PTEN PIK3CA HRAS
36 thyroid carcinoma 31.4 PTEN PIK3CA HRAS BRAF
37 mantle cell lymphoma 31.3 TP53 PTEN PIK3CA CTNNB1
38 kidney cancer 31.3 TP53 PTEN PIK3CA MIR199A1 H2AC18
39 liposarcoma 31.3 TP53 PTEN PIK3CA CTNNB1
40 lynch syndrome 31.3 TP53 SMAD4 PTEN PIK3CA HRAS H2AC18
41 lymphoma, non-hodgkin, familial 31.3 U2AF1 TP53 SERPINA3 PTEN PIK3CA MIR331
42 small cell cancer of the lung 31.3 U2AF1 TP53 PTEN PIK3CA
43 acute cystitis 31.3 SERPINA3 KLK3 H2AC18
44 gastric adenocarcinoma 31.3 TP53 SMAD4 PTEN PIK3CA IDH1 HRAS
45 esophageal cancer 31.3 TP53 SMAD4 PTEN PIK3CA MIR199A1 MIR145
46 glioblastoma multiforme 31.3 TP53 PTEN PIK3CA IDH1 HRAS FOLH1
47 skin melanoma 31.3 U2AF1 TP53 PTEN MIR199A1 HRAS H2AC18
48 adenoid cystic carcinoma 31.3 TP53 SERPINA3 PTEN PIK3CA IDH1 HRAS
49 cystadenocarcinoma 31.2 TP53 SERPINA3 PIK3CA MIR199A1 HRAS BRAF
50 glioma 31.2 TP53 PTEN PIK3CA IDH1 BRAF

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

Clinical features from OMIM:

601188

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.32 PTEN

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 AR BRAF CTNNB1 HRAS KLF6 KLK3
2 endocrine/exocrine gland MP:0005379 10.14 AR BRAF CTNNB1 HRAS KLF6 NKX3-1
3 embryo MP:0005380 10.13 AR BRAF CTNNB1 KLF6 NKX3-1 PIK3CA
4 integument MP:0010771 10.07 AR BRAF CTNNB1 HRAS KLF6 PIK3CA
5 digestive/alimentary MP:0005381 10.06 AR BRAF CTNNB1 HRAS NKX3-1 PTEN
6 limbs/digits/tail MP:0005371 9.87 AR BRAF CTNNB1 NKX3-1 PTEN SMAD4
7 muscle MP:0005369 9.86 AR BRAF CTNNB1 KLK3 PIK3CA PTEN
8 neoplasm MP:0002006 9.85 AR BRAF CTNNB1 HRAS NKX3-1 PIK3CA
9 reproductive system MP:0005389 9.65 AR BRAF CTNNB1 KLF6 NKX3-1 PIK3CA
10 skeleton MP:0005390 9.32 AR BRAF CTNNB1 HRAS IDH1 NKX3-1

Drugs & Therapeutics for Suppression of Tumorigenicity 12

Drugs for Suppression of Tumorigenicity 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fesoterodine Approved Phase 4 286930-02-7, 286930-03-8 6918558
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Prilocaine Approved Phase 4 721-50-6 4906
4
Tranexamic Acid Approved Phase 4 1197-18-8 5526
5 Cholinergic Agents Phase 4
6 Muscarinic Antagonists Phase 4
7 Cholinergic Antagonists Phase 4
8 Sodium Channel Blockers Phase 4
9 Anti-Arrhythmia Agents Phase 4
10 Anesthetics, Local Phase 4
11 Diuretics, Potassium Sparing Phase 4
12 Hemostatics Phase 4
13 Antifibrinolytic Agents Phase 4
14 Coagulants Phase 4
15
Norepinephrine Approved Phase 3 51-41-2 439260
16
Zoledronic Acid Approved Phase 3 118072-93-8 68740
17
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
18
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
19
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
20
Cyproterone Acetate Approved, Investigational Phase 3 427-51-0
21
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
22
Iodine Approved, Investigational Phase 3 7553-56-2 807
23
Choline Approved, Nutraceutical Phase 3 62-49-7 305
24 Bombesin Investigational Phase 2, Phase 3 31362-50-2
25 Antidepressive Agents Phase 3
26 Venlafaxine Hydrochloride Phase 3
27 Psychotropic Drugs Phase 3
28 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
29 Adrenergic alpha-Antagonists Phase 3
30 Adrenergic Agents Phase 3
31 Adrenergic Antagonists Phase 3
32 Adrenergic alpha-1 Receptor Antagonists Phase 3
33 Contraceptives, Oral Phase 3
34 Contraceptive Agents, Male Phase 3
35
Cyproterone Phase 3 2098-66-0 5284537
36
Medroxyprogesterone Phase 3 520-85-4 10631
37 Neurotransmitter Agents Phase 2, Phase 3
38 Tubulin Modulators Phase 2, Phase 3
39 Antimitotic Agents Phase 2, Phase 3
40 Anesthetics Phase 3
41 cadexomer iodine Phase 3
42 gastrin-releasing peptide Phase 2, Phase 3
43 Radiopharmaceuticals Phase 2, Phase 3
44 Androgens Phase 3
45 Gastrointestinal Agents Phase 3
46 Lipid Regulating Agents Phase 3
47 Hypolipidemic Agents Phase 3
48 Antimetabolites Phase 3
49 Prolactin Release-Inhibiting Factors Phase 3
50
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 187)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy ) Completed NCT01661166 Phase 4 Fesoterodine;Placebo oral tablet
2 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel;periprostatic nerve blockade
3 Can the Prophylactic Administration of Tranexamic Acid Reduce Blood Loss After Robotic-assisted Radical Prostatectomy? The RARPEX (Robotic Assisted Radical Prostatectomy With TranEXamic Acid) Study. Recruiting NCT04319614 Phase 4 Tranexamic Acid Injectable Product;Placebos
4 Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer. Unknown status NCT02258087 Phase 2, Phase 3
5 Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers Unknown status NCT00104715 Phase 3 antiandrogen therapy;docetaxel;goserelin acetate
6 Phase III Clinical Trial on Conventionally Fractionated Conformal Radiotherapy (CF-CRT) Versus CF-CRT Combined With High-dose-rate Brachytherapy or Stereotactic Body Radiotherapy for Intermediate and High-risk Prostate Cancer. Unknown status NCT01839994 Phase 3 Hormonal treatment (neoadjuvant androgen deprivation)
7 Economic Evaluation of Image Guided Radiation Therapy For Prostate Cancer Completed NCT00433706 Phase 3
8 A Randomized Trial of Tamsulosin and/or Dutasteride Versus Placebo to Relieve Urinary Symptoms After Brachytherapy for the Treatment of Localized Prostate Cancer Completed NCT00244309 Phase 3 tamsulosin and/or dutasteride
9 Efficacy and Tolerance of Cyproterone Acetate Versus Medroxyprogesterone Acetate Versus Venlafaxine LP in the Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Patients Treated for a Prostate Adenocarcinoma Completed NCT01011751 Phase 3 Cyproterone acetate;Medroxyprogesterone acetate;Venlafaxine;Leuprorelin;Flutamide;Placebo
10 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
11 International Randomised Study of Laparoscopic Prostatectomy vs Stereotactic Body Radiotherapy (SBRT) and Conventionally Fractionated Radiotherapy vs SBRT for Early Stage Organ-Confined Prostate Cancer Recruiting NCT01584258 Phase 3
12 68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans Recruiting NCT02624518 Phase 2, Phase 3 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
13 68Ga-PSMA-11 PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer Recruiting NCT02678351 Phase 2, Phase 3 gallium Ga 68-PSMA-11
14 A Phase II Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial Recruiting NCT01411345 Phase 2, Phase 3
15 PALS: Prostate Cancer Active Lifestyle Study Recruiting NCT02454517 Phase 3
16 Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel Recruiting NCT03070886 Phase 2, Phase 3 Bicalutamide;Docetaxel;Flutamide;Goserelin Acetate;Leuprolide Acetate;Nilutamide
17 Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Recruiting NCT03367702 Phase 3
18 A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer Recruiting NCT02692105 Phase 3
19 Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer. Active, not recruiting NCT02175212 Phase 3 Short term androgen deprivation;Long term androgen deprivation
20 Randomized, Multicentre, Phase III Study in Patients With Intermediate-risk T1 T2 Prostate Adenocarcinomas, to Verify the Role of Six Months of Total Androgen Blockade for Two Dosage Levels of Prostate Radiation Therapy (70 Gy and 76 Gy) Versus Prostate Radiation Therapy Alone at 76 Gy Active, not recruiting NCT00223145 Phase 3 Androgen blockade
21 A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT) Active, not recruiting NCT03274687 Phase 3
22 Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study Enrolling by invitation NCT03404648 Phase 3 C-11 choline PET tracer;Gadobutrol
23 A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse Suspended NCT01952223 Phase 3 Cabazitaxel
24 A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate Unknown status NCT01255891 Phase 2
25 Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer Unknown status NCT02031328 Phase 1, Phase 2
26 A Phase II Open Label Trial of Amifostine Plus Fractionated Radiotherapy for Primary Prostate Adenocarcinoma (T1a-T3b, NoMo, PSA>10 ng/ml) to Estimate Acute Grade 2 Genitourinary and Gastrointestinal Toxicity Completed NCT00003307 Phase 2 amifostine trihydrate
27 A Phase II Pilot Study of Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Completed NCT00183924 Phase 2 Estramustine;Docetaxel;Carboplatin
28 C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma Completed NCT01530269 Phase 2 C11-Sodium Acetate
29 Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer Completed NCT01898065 Phase 2 18-F-MISO
30 A Phase II Study Using Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate Completed NCT00585962 Phase 2
31 Phase II Evaluation of Early Oral Estramustine, Oral Etoposide and Intravenous Paclitaxel in Patients With Hormonally Responsive Adenocarcinoma of the Prostate Completed NCT00151060 Phase 2 Estramustine;Etoposide;Paclitaxel
32 Phase IIA, Randomized Placebo-Controlled Trial of Single High Dose Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer Undergoing Prostatectomy Completed NCT01325311 Phase 2 Cholecalciferol;Genistein
33 A Trial Of Neoadjuvant Androgen Supression And Dose Escalation Transperineal Ultrasound-Guided Brachytherapy For Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy Completed NCT00032006 Phase 2
34 Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Completed NCT01787331 Phase 2 Itraconazole
35 Neoadjuvant Androgen Depletion in Combination With Vorinostat Followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) Completed NCT00589472 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate;Vorinostat
36 Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy Completed NCT00582556 Phase 2 Zometa;zometa;Zometa
37 A Phase II Immunotherapeutic Trial: Combination Androgen Ablative Therapy and CTLA-4 Blockade as a Treatment for Advanced Prostate Cancer Completed NCT00170157 Phase 2 Bicalutamide;Flutamide;Goserelin Acetate;Ipilimumab;Leuprolide Acetate
38 A Randomized Phase II Study of Androgen Deprivation Combined With IMC-A12 Versus Androgen Deprivation Alone for Patients With New Hormone Sensitive Metastatic Prostate Cancer Completed NCT01120236 Phase 2 Bicalutamide;Goserelin Acetate;Leuprolide Acetate
39 Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer (Hypo-FLAME) Completed NCT02853110 Phase 2
40 BMS CA180-097: A Phase II Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer, Previously Treated With Chemotherapy Completed NCT00570700 Phase 2 Dasatinib
41 A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy. Completed NCT01194271 Phase 2 Leuprolide Acetate;Ipilimumab
42 Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes Recruiting NCT03762759 Phase 2 Fluciclovine F18
43 Carbohydrate and Prostate Study 3: Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance Recruiting NCT03679260 Phase 2
44 Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate Recruiting NCT02944201 Phase 2 Carvedilol
45 Phase II Trial of Hypofractionated Proton Beam Therapy in Men With Localized Prostate Adenocarcinoma Recruiting NCT01950351 Phase 2
46 A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation Recruiting NCT02805894 Phase 1, Phase 2 NBTXR3 activated by IMRT only;NBTXR3 activated by Brachytherapy & IMRT
47 PSMA PET Imaging of Recurrent Prostate Cancer Recruiting NCT03204123 Phase 2 Ga-HBED-iPSMA PET
48 68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer Recruiting NCT03113617 Phase 2 Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
49 Hyperpolarized 13-C-Pyruvate Magnetic Resonance Spectroscopic Imaging Reproducibilty Pilot in Patients With Prostate Cancer Recruiting NCT03581500 Phase 2 Hyperpolarized Carbon C 13 Pyruvate
50 WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy Recruiting NCT03824652 Phase 2

Search NIH Clinical Center for Suppression of Tumorigenicity 12

Genetic Tests for Suppression of Tumorigenicity 12

Anatomical Context for Suppression of Tumorigenicity 12

MalaCards organs/tissues related to Suppression of Tumorigenicity 12:

40
Prostate, Bone, Lymph Node, Brain, Endothelial, Lung, Breast

Publications for Suppression of Tumorigenicity 12

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 2620)
# Title Authors PMID Year
1
Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11. 61 56
8637912 1996
2
Identification of a natural compound, sesamin, as a novel TRPM8 antagonist with inhibitory effects on prostate adenocarcinoma. 61
32439453 2020
3
Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer. 61
32420037 2020
4
Cystic brain metastasis from prostate cancer: A case report and literature review. 61
32382510 2020
5
Successive xanthogranulomatous prostatitis after complete remission of metastatic prostate adenocarcinoma: An extremely rare case report with review of literatures. 61
32292700 2020
6
Metastatic Parathyroid Hormone-Secreting Prostate Adenocarcinoma Mimicking Ectopic Parathyroid Adenoma Demonstrated on 99mTc-MIBI Image. 61
32453086 2020
7
Focal 18F-NaF PET Prostate Activity in the Setting of Prostate Adenocarcinoma. 61
32404713 2020
8
Prostate adenorcarcinoma revealed by gingival metastasis: An uncommon presentation. 61
32322507 2020
9
Synchronous detection of SDHA-related gallbladder paraganglioma and pancreatic neuroendocrine tumor. 61
32534711 2020
10
Machine learning application for incident prostate adenocarcinomas automatic registration in a French regional cancer registry. 61
32330852 2020
11
MINDIN secretion by prostate tumors induces premetastatic changes in bone via β-catenin. 61
32357310 2020
12
Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer. 61
32562536 2020
13
Usefulness of 18F-Choline Positron Emission Tomography - Computed Tomography in the therapeutic management of patients with biochemical recurrence of prostate adenocarcinoma treated with brachytherapy. 61
32576406 2020
14
Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. 61
32111660 2020
15
Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy. 61
32519025 2020
16
Race Does Not Affect Survival in Patients With Prostate Cancer Treated With Radiation Therapy. 61
32487626 2020
17
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. 61
32403054 2020
18
Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT. 61
32520499 2020
19
Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy. 61
32552802 2020
20
Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells. 61
32531951 2020
21
Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development. 61
32512818 2020
22
68Ga-Prostate-Specific Membrane Antigen Uptake in Dissecting Abdominal Aortic Aneurysm. 61
32149812 2020
23
Prostate Cancer Brain Metastases: A Single-Institution Experience. 61
32147556 2020
24
Ureteral Metastasis From Prostate Cancer: A PSMA PET Pitfall. 61
32558720 2020
25
EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. 61
32362422 2020
26
Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. 61
31882336 2020
27
Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study. 61
32496350 2020
28
Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure. 61
31987961 2020
29
Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent. 61
31742696 2020
30
Metastatic Prostate Adenocarcinoma of the Mandible Diagnosed With Oral Manifestations. 61
31688259 2020
31
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. 61
32468052 2020
32
Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate Cancer. 61
32366454 2020
33
Acquired reactive perforating collagenosis in association with prostate adenocarcinoma, chronic lymphocytic leukemia, and Graves' disease. 61
32359703 2020
34
Ancestry-specific predisposing germline variants in cancer. 61
32471518 2020
35
Fever of unknown origin, a rare presentation of metastatic prostate cancer: Case report. 61
32025497 2020
36
MRI-guided pelvic lymph node biopsy via transrectal approach in prostate cancer. 61
32071877 2020
37
The decline of FANCM immunohistochemical expression in prostate cancer stroma correlates with the grade group. 61
32462745 2020
38
Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer. 61
32119599 2020
39
Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis. 61
32527134 2020
40
The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. 61
32392735 2020
41
TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. 61
31371409 2020
42
Co-occurrence of multiple endocrine neoplasia type 4 and spinal neurofibromatosis: a case report. 61
32052251 2020
43
Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b). 61
32234886 2020
44
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma. 61
32106037 2020
45
68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination? 61
32049736 2020
46
Comprehensive Analysis Identifying Wnt Ligands Gene Family for Biochemical Recurrence in Prostate Adenocarcinoma and Construction of a Nomogram. 61
32298604 2020
47
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. 61
32285460 2020
48
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. 61
32368717 2020
49
Metastatic prostate cancer to an ischiorectal fossa lymph node identified on multiparametric magnetic resonance imaging. 61
32565657 2020
50
Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100. 61
32017163 2020

Variations for Suppression of Tumorigenicity 12

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

6 (show top 50) (show all 186) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TP53 NM_000546.6(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
2 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
3 TP53 NM_001126112.2(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
4 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
5 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
6 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
7 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
8 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
9 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
10 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
11 TP53 NM_001126112.2(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
12 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
13 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
14 BRAF NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)SNV Pathogenic 13970 rs121913357 7:140481403-140481403 7:140781603-140781603
15 BRAF NM_001374258.1(BRAF):c.1526G>C (p.Gly509Ala)SNV Pathogenic 13971 rs121913355 7:140481402-140481402 7:140781602-140781602
16 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu)SNV Pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
17 PIK3CA NM_006218.4(PIK3CA):c.1258T>C (p.Cys420Arg)SNV Pathogenic 31945 rs121913272 3:178927980-178927980 3:179210192-179210192
18 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
19 BRAF NM_001374258.1(BRAF):c.1526G>T (p.Gly509Val)SNV Pathogenic 44803 rs121913355 7:140481402-140481402 7:140781602-140781602
20 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
21 BRAF NM_001374258.1(BRAF):c.1921A>G (p.Lys641Glu)SNV Pathogenic 13966 rs121913364 7:140453134-140453134 7:140753334-140753334
22 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
23 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
24 TP53 NM_001126112.2(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
25 TP53 NM_001126112.2(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
26 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
27 PTEN NM_000314.7(PTEN):c.389G>C (p.Arg130Pro)SNV Pathogenic 142018 rs121909229 10:89692905-89692905 10:87933148-87933148
28 TP53 NM_001126112.2(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
29 IDH1 NM_001282386.1(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
30 TP53 NM_001126112.2(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
31 TP53 NM_001126112.2(TP53):c.743G>C (p.Arg248Pro)SNV Pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
32 PIK3CA NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys)SNV Pathogenic 376050 rs121913284 3:178921553-178921553 3:179203765-179203765
33 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
34 TP53 NM_001126112.2(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
35 TP53 NM_001126112.2(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
36 TP53 NM_001126112.2(TP53):c.523C>G (p.Arg175Gly)SNV Pathogenic 376649 rs138729528 17:7578407-7578407 17:7675089-7675089
37 TP53 NM_001126112.2(TP53):c.734G>T (p.Gly245Val)SNV Pathogenic/Likely pathogenic 376603 rs121912656 17:7577547-7577547 17:7674229-7674229
38 TP53 NM_001126112.2(TP53):c.817C>A (p.Arg273Ser)SNV Pathogenic/Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
39 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro)SNV Pathogenic/Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
40 TP53 NM_001126112.2(TP53):c.700T>C (p.Tyr234His)SNV Pathogenic/Likely pathogenic 376691 rs864622237 17:7577581-7577581 17:7674263-7674263
41 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
42 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
43 IDH1 NM_001282386.1(IDH1):c.395G>T (p.Arg132Leu)SNV Pathogenic/Likely pathogenic 375889 rs121913500 2:209113112-209113112 2:208248388-208248388
44 IDH1 NM_001282386.1(IDH1):c.394C>G (p.Arg132Gly)SNV Pathogenic/Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
45 IDH1 NM_001282386.1(IDH1):c.394C>A (p.Arg132Ser)SNV Pathogenic/Likely pathogenic 375893 rs121913499 2:209113113-209113113 2:208248389-208248389
46 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr)SNV Pathogenic/Likely pathogenic 375894 rs121913403 3:41266113-41266113 3:41224622-41224622
47 CTNNB1 NM_001904.4(CTNNB1):c.134C>A (p.Ser45Tyr)SNV Pathogenic/Likely pathogenic 375895 rs121913409 3:41266137-41266137 3:41224646-41224646
48 PIK3CA NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)SNV Pathogenic/Likely pathogenic,drug response 375896 rs104886003 3:178936091-178936091 3:179218303-179218303
49 PIK3CA NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro)SNV Pathogenic/Likely pathogenic 375898 rs397517201 3:178936095-178936095 3:179218307-179218307
50 PIK3CA NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu)SNV Pathogenic/Likely pathogenic 375899 rs397517201 3:178936095-178936095 3:179218307-179218307

Expression for Suppression of Tumorigenicity 12

Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.

Pathways for Suppression of Tumorigenicity 12

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 TP53 SMAD4 PIK3CA HRAS CTNNB1 BRAF
2
Show member pathways
12.82 TP53 SMAD4 PTEN H2AC18 AR
3
Show member pathways
12.72 TP53 SMAD4 PTEN PIK3CA HRAS CTNNB1
4
Show member pathways
12.7 TP53 PTEN PIK3CA HRAS CTNNB1 BRAF
5
Show member pathways
12.67 TP53 PTEN PIK3CA HRAS BRAF
6
Show member pathways
12.61 TP53 PTEN PIK3CA HRAS BRAF
7
Show member pathways
12.49 TP53 PTEN PIK3CA HRAS BRAF
8
Show member pathways
12.48 TP53 SMAD4 PTEN PIK3CA HRAS CTNNB1
9 12.47 TP53 PTEN PIK3CA MIR331 MIR199A1 MIR145
10
Show member pathways
12.39 PTEN PIK3CA HRAS BRAF
11
Show member pathways
12.38 PIK3CA HRAS CTNNB1 BRAF
12
Show member pathways
12.38 TP53 PTEN PIK3CA HRAS
13 12.38 TP53 SMAD4 PTEN PIK3CA NKX3-1 KLK3
14 12.32 TP53 SMAD4 PTEN PIK3CA HRAS
15
Show member pathways
12.29 PIK3CA HRAS CTNNB1 BRAF
16 12.29 TP53 PIK3CA HRAS CTNNB1 BRAF
17
Show member pathways
12.21 TP53 PTEN PIK3CA HRAS BRAF AR
18 12.18 TP53 SMAD4 CTNNB1 BRAF
19
Show member pathways
12.17 TP53 PIK3CA HRAS BRAF
20 12.14 TP53 PTEN PIK3CA HRAS
21
Show member pathways
12.11 TP53 TMPRSS2 SMAD4 PTEN PIK3CA NKX3-1
22
Show member pathways
12.09 PIK3CA HRAS BRAF
23 12.09 SMAD4 PIK3CA HRAS CTNNB1
24
Show member pathways
12.06 SMAD4 PTEN PIK3CA HRAS BRAF
25 12.03 TP53 SMAD4 PTEN CTNNB1 BRAF AR
26
Show member pathways
12.02 PIK3CA HRAS CTNNB1 BRAF
27
Show member pathways
12.02 TP53 PTEN PIK3CA KLK3 HRAS CTNNB1
28 12 TP53 PIK3CA HRAS CTNNB1
29 11.99 TP53 PTEN PIK3CA HRAS
30 11.94 TP53 PTEN HRAS CTNNB1 BRAF
31 11.9 TP53 SMAD4 PTEN HRAS BRAF
32 11.81 SMAD4 PTEN KLK3 CTNNB1 AR
33
Show member pathways
11.8 PIK3CA HRAS BRAF
34 11.79 TP53 SMAD4 PTEN PIK3CA HRAS CTNNB1
35 11.73 TP53 HRAS BRAF
36 11.69 PIK3CA HRAS BRAF
37 11.68 TP53 PTEN PIK3CA HRAS
38 11.65 TP53 PTEN PIK3CA IDH1 HRAS
39 11.62 SMAD4 HRAS CTNNB1
40 11.58 PTEN PIK3CA HRAS
41 11.58 TP53 PTEN PIK3CA
42 11.54 TMPRSS2 KLK3 AR
43 11.49 SMAD4 MIR145 CTNNB1
44
Show member pathways
11.49 NKX3-1 KLK3 AR
45 11.48 TMPRSS2 NKX3-1 KLK3 CTNNB1 AR
46 11.26 PTEN PIK3CA HRAS
47 11.25 SMAD4 HRAS CTNNB1
48
Show member pathways
11.2 SMAD4 PIK3CA HRAS
49 11 PIK3CA HRAS AR

GO Terms for Suppression of Tumorigenicity 12

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 TP53 SMAD4 NKX3-1 KLF6 HRAS CTNNB1
2 positive regulation of transcription, DNA-templated GO:0045893 9.88 TP53 SMAD4 NKX3-1 KLF6 CTNNB1 AR
3 heart development GO:0007507 9.85 TP53 PTEN NKX3-1 CTNNB1
4 in utero embryonic development GO:0001701 9.84 TP53 SMAD4 CTNNB1 AR
5 regulation of cell proliferation GO:0042127 9.83 TP53 SMAD4 CTNNB1 BRAF
6 cellular response to drug GO:0035690 9.69 TP53 NKX3-1 BRAF
7 negative regulation of epithelial cell proliferation GO:0050680 9.65 PTEN NKX3-1 AR
8 seminiferous tubule development GO:0072520 9.56 SMAD4 AR
9 protein kinase B signaling GO:0043491 9.5 PTEN PIK3CA NKX3-1
10 positive regulation of gene expression GO:0010628 9.5 TP53 PTEN NKX3-1 HRAS CTNNB1 BRAF
11 prostate gland growth GO:0060736 9.46 PTEN AR
12 regulation of axon regeneration GO:0048679 9.43 PTEN BRAF
13 androgen receptor signaling pathway GO:0030521 9.43 NKX3-1 CTNNB1 AR
14 epithelial cell differentiation involved in prostate gland development GO:0060742 9.37 CTNNB1 AR
15 negative regulation of cell proliferation GO:0008285 9.17 TP53 SMAD4 PTEN NKX3-1 HRAS CTNNB1
16 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.16 CTNNB1 AR

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.46 TP53 SMAD4 NKX3-1 AR
2 transcription regulatory region sequence-specific DNA binding GO:0000976 9.35 TP53 SMAD4 NKX3-1 KLF6 AR
3 I-SMAD binding GO:0070411 9.26 SMAD4 CTNNB1
4 RNA polymerase II transcription factor binding GO:0001085 8.92 TP53 SMAD4 CTNNB1 AR

Sources for Suppression of Tumorigenicity 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....